The CDC Advisory Committee on Immunization Practices (ACIP) recently recommended Pfizer and BioNTech’s pediatric COVID-19 vaccine for children five to 11 years of age.
The organization now...
The US government recently purchased additional doses of Eli Lilly and Company’s combination COVID-19 antibody treatment.
Under the agreement, Eli Lilly and Company will supply 614,000 doses of...
Moderna recently dosed the first participant in the Phase 3 pivotal registration study of its cytomegalovirus (CMV) mRNA vaccine candidate, mRNA-1647.
The CMVictory study will evaluate the safety and...
FDA recently granted emergency use authorization to Thermo Fisher Scientific to run new saliva sample collection methods on its COVID-19 tests.
The company’s molecular diagnostics Spectrum...
FDA recently granted emergency use authorization to Pfizer and BioNTech’s COVID-19 vaccine for children five through 11 years of age.
The agency based its decision on data from a Phase 2/3...
Moderna recently announced that two doses of its COVID-19 vaccine showed a robust neutralizing antibody response in children six to under 12 years of age.
The Phase 2/3 KidCOVE randomized...
Pfizer and BioNTech recently announced that their COVID-19 vaccine booster was 95.6 percent effective in individuals compared to placebo.
The randomized, controlled Phase 3 trial...
CDC recently recommended Johnson & Johnson and Moderna’s COVID-19 vaccine booster shots for all eligible individuals who receive any FDA authorized vaccine.
The organization...
FDA recently granted emergency use authorization to both the Moderna and Johnson & Johnson respective COVID-19 vaccine booster doses.
The agency specifically approved Moderna’s booster...
FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) recently recommended a booster dose of Moderna’s COVID-19 vaccine, mRNA-1273, at the 50 microgram...
FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) recently recommended emergency use authorization for a booster dose of Johnson & Johnson’s COVID-19 vaccine.
VRBPAC...
AstraZeneca recently announced that its COVID-19 antibody, AZD7442, reduced severe COVID-19 or death compared to placebo in non-hospitalized patients with mild-to-moderate symptomatic...
Moderna recently announced that it will build a state-of-the-art mRNA facility in Africa to produce up to 500 million doses of vaccines annually at the 50 microgram dose level.
The company will invest...
Johnson & Johnson recently announced that Paul Stoffels, MD, current vice-chairman of the executive committee and chief scientific officer of Johnson & Johnson, will retire at the end of...
Johnson & Johnson recently submitted data to the FDA to support its COVID-19 vaccine booster shot in adults 18 and older.
The submission includes results from the Phase 3 ENSEMBLE study, which...
AstraZeneca recently submitted a request to FDA for an emergency use authorization for its long-acting COVID-19 antibody combination, AZD7442.
AstraZeneca optimized AZD7442 using its YTE half-life...
Francis S. Collins, MD, PhD, will be stepping down as director of the National Institutes of Health (NIH) by the end of 2021.
Collins is the longest-serving presidentially appointed NIH director,...
Regeneron recently announced that its COVID-19 antibody cocktail, REGEN-COV, significantly reduced viral load in patients hospitalized with the coronavirus.
The trial enrolled 1,197 patients to...
Pfizer and BioNTech recently submitted data to FDA from the Phase 2/3 clinical trial of their COVID-19 vaccine in children five to 11 years of age.
Last week, the companies announced that...
Pfizer recently announced the start of a Phase 2/3 study to evaluate its COVID-19 treatment in combination with ritonavir to prevent coronavirus disease.
The randomized, double-blind EPIC-PEP study...
